EUVIMEDEUVIMED entdecken
Crossref

The Case for Curiosity-Driven Research: New Treatments for Cancer and Anemia Emerging from Studies of an Obscure Hereditary Cancer Syndrome

William Kaelin

Proceedings of the American Philosophical Society · 2026-06 · 167 (2) · 79-95

DOI: 10.1353/pro.2026.a992575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the American Philosophical Society, 2026-06. Verfasst von William Kaelin.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ABSTRACTS: von Hippel-Lindau (VHL) Disease, which was described in the medical literature about a century ago, presents as a hereditary cancer syndrome and is caused by inactivating mutations of the VHL tumor suppressor gene. VHL patients are at high risk for kidney cancers, blood vessel tumors called hemangioblastomas, and neural crest tumors called paragangliomas. VHL mutations, now as acquired mutations rather than inherited mutations, also play important roles in the non-hereditary counterparts of these tumors. VHL-associated tumors often stimulate angiogenesis and red blood cell production due to overproduction of VEGF and erythropoietin, respectively, both of which are normally induced by low oxygen (hypoxia). This was a clue that the VHL protein likely played a role in oxygen sensing. Many hypoxia-inducible genes are regulated by a transcription factor called HIF (hypoxia-inducible factor), which contains an unstable alpha subunit and a stable beta subunit. We and others showed that the VHL protein binds to the HIF alpha subunits and targets them for destruction, but only if the latter have undergone oxygen-dependent hydroxylation of conserved prolyl residues by the EglN family of prolyl hydroxylases. Under low oxygen conditions, EglN activity falls and HIF levels rise. Drugs that inhibit HIF, and particularly HIF2, are now approved to treat sporadic kidney cancer and VHL disease. Conversely, multiple EglN inhibitors, which stabilize HIF, are approved for the treatment of anemia.

Zitieren

APA

Kaelin, W. (2026). The Case for Curiosity-Driven Research: New Treatments for Cancer and Anemia Emerging from Studies of an Obscure Hereditary Cancer Syndrome. Proceedings of the American Philosophical Society, 167(2), 79-95. https://doi.org/10.1353/pro.2026.a992575

Vancouver

Kaelin W. The Case for Curiosity-Driven Research: New Treatments for Cancer and Anemia Emerging from Studies of an Obscure Hereditary Cancer Syndrome. Proceedings of the American Philosophical Society. 2026;167(2):79-95. doi:10.1353/pro.2026.a992575

BibTeX
@article{Kaelin2026,
  author = {Kaelin, William},
  title = {The Case for Curiosity-Driven Research: New Treatments for Cancer and Anemia Emerging from Studies of an Obscure Hereditary Cancer Syndrome},
  journal = {Proceedings of the American Philosophical Society},
  year = {2026},
  volume = {167},
  number = {2},
  pages = {79--95},
  doi = {10.1353/pro.2026.a992575}
}
Kostenlos starten →